Cargando…

Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases

Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Anyfanti, Panagiota, Dara, Athanasia, Angeloudi, Elena, Bekiari, Eleni, Dimitroulas, Theodoros, Kitas, George D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684400/
https://www.ncbi.nlm.nih.gov/pubmed/34934338
http://dx.doi.org/10.2147/JIR.S276986
_version_ 1784617611730878464
author Anyfanti, Panagiota
Dara, Athanasia
Angeloudi, Elena
Bekiari, Eleni
Dimitroulas, Theodoros
Kitas, George D
author_facet Anyfanti, Panagiota
Dara, Athanasia
Angeloudi, Elena
Bekiari, Eleni
Dimitroulas, Theodoros
Kitas, George D
author_sort Anyfanti, Panagiota
collection PubMed
description Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach.
format Online
Article
Text
id pubmed-8684400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86844002021-12-20 Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases Anyfanti, Panagiota Dara, Athanasia Angeloudi, Elena Bekiari, Eleni Dimitroulas, Theodoros Kitas, George D J Inflamm Res Review Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach. Dove 2021-12-14 /pmc/articles/PMC8684400/ /pubmed/34934338 http://dx.doi.org/10.2147/JIR.S276986 Text en © 2021 Anyfanti et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Anyfanti, Panagiota
Dara, Athanasia
Angeloudi, Elena
Bekiari, Eleni
Dimitroulas, Theodoros
Kitas, George D
Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title_full Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title_fullStr Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title_full_unstemmed Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title_short Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
title_sort monitoring and managing cardiovascular risk in immune mediated inflammatory diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684400/
https://www.ncbi.nlm.nih.gov/pubmed/34934338
http://dx.doi.org/10.2147/JIR.S276986
work_keys_str_mv AT anyfantipanagiota monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases
AT daraathanasia monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases
AT angeloudielena monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases
AT bekiarieleni monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases
AT dimitroulastheodoros monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases
AT kitasgeorged monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases